With 0.54 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.26 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $23.109 whereas the lowest price it dropped to was $21.09. The 52-week range on SEPN shows that it touched its highest point at $28.99 and its lowest point at $4.17 during that stretch. It currently has a 1-year price target of $24.25. Beta for the stock currently stands at 4.10.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SEPN was up-trending over the past week, with a rise of 18.37%, but this was up by 47.77% over a month. Three-month performance surged to 92.55% while six-month performance rose 348.01%. A look at the trailing 12-month EPS for SEPN yields -2.15 with Next year EPS estimates of -2.07. For the next quarter, that number is 0.04. This implies an EPS growth rate of 95.16% for this year and -490.28% for next year.
Float and Shares Shorts:
At present, 44.57 million SEPN shares are outstanding with a float of 26.76 million shares on hand for trading. On 2025-09-15, short shares totaled 3.17 million, which was 711.00004 higher than short shares on 1755216000. In addition to Dr. Jeffrey T. Finer M.D., Ph.D. as the firm’s Co-Founder, CEO & Director, Ms. Elizabeth P. Bhatt M.B.A., M.S. serves as its President & COO.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, SEPN reported revenue of $119000.0 and operating income of -$28978000.0. The EBITDA in the recently reported quarter was -$28573000.0 and diluted EPS was -$0.56.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With SEPN analysts setting a high price target of 28.0 and a low target of 18.0, the average target price over the next 12 months is 24.25. Based on these targets, SEPN could surge 24.5% to reach the target high and fall by -19.96% to reach the target low. Reaching the average price target will result in a growth of 7.83% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$5.19 being high and -$10.38 being low. For SEPN, this leads to a yearly average estimate of -$7.11. The surprise factor in the prior quarter was -$0.45. Based on analyst estimates, the high estimate for the next quarter is $0.87 and the low estimate is -$0.52. The average estimate for the next quarter is thus -$0.17.
